Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone

Hypertension

Volumn 49, Issue 3, 2007, Pages 563-568

  Toth, Janos ^a,b   Racz, Anita ^a   Kaminski, Pawel M ^b   Wolin, Michael S ^b   Bagi, Zsolt ^c   Koller, Akos ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

ADMA; Arteriolar tone; Flow dependent dilation; Nitric oxide; Superoxide

Indexed keywords

8 BROMO CYCLIC GMP; INDOMETACIN; MACROGOL; N(G),N(G) DIMETHYLARGININE; NIFEDIPINE; NITRIC OXIDE; SUPEROXIDE DISMUTASE;

ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD FLOW; BLOOD VESSEL TONE; CHEMOLUMINESCENCE; CONTROLLED STUDY; FLUORESCENCE; GRACILIS MUSCLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHEAR STRESS; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ARGININE; ARTERIOLES; ENZYME INHIBITORS; MALE; MODELS, ANIMAL; MUSCLE, SKELETAL; NITRIC OXIDE; RATS; RATS, WISTAR; SHEAR STRENGTH; STRESS, MECHANICAL; SUPEROXIDES; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

EID: 33847068349     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000256764.86208.3d     Document Type: Article

References (41)

1. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol. 2002;53:503-514.
2. Sun D, Messina EJ, Koller A, Wolin MS, Kaley G. Endotheliumdependent dilation to L-arginine in isolated rat skeletal muscle arterioles. Am J Physiol. 1992;262:H1211-H1216.
3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
4. Hedner T, Himmelmann A, Hansson L. Homocysteine and ADMA-emerging risk factors for cardiovascular disease? Blood Press. 2002;11:197-200.
5. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51:843-846.
6. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987-992.
7. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-2128.
8. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068-2074.
9. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001;37:489-492.
10. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension. 2006;48:278-285.
11. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146.
12. Bode-Boger SM, Muke J, Surdacki A, Brabant G, Boger RH, Frolich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8:77-81.
13. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
14. Koller A, Kaley G. Endothelium regulates skeletal muscle microcirculation by a blood flow velocity-sensing mechanism. Am J Physiol. 1990;258:H916-H920.
15. Koller A, Sun D, Huang A, Kaley G. Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation of rat gracilis muscle arterioles. Am J Physiol. 1994;267:H326-H332.
16. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke. 2006;37:2024-2029.
17. Koller A, Sun D, Messina EJ, Kaley G. L-arginine analogues blunt prostaglandin-related dilation of arterioles. Am J Physiol. 1993;264:H1194-H1199.
18. Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, Kaley G. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res. 2002;90:1159-1166.
19. Koller A, Huang A. Shear stress-induced dilation is attenuated in skeletal muscle arterioles of hypertensive rats. Hypertension. 1995;25:758-763.
20. Teerlink T. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. In press.
21. Martens-Lobenhoffer J, Bode-Boger SM. Chromatographic-mass spectrometric methods for the quantification of l-arginine and its methylated metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. In press.
22. Scalera F, Martens-Lobenhoffer J, Tager M, Bukowska A, Lendeckel U, Bode-Boger SM. Effect of L-arginine on asymmetric dimethylarginine (ADMA) or homocysteine-accelerated endothelial cell aging. Biochem Biophys Res Commun. 2006;345:1075-1082.
23. Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med. 2005;10(suppl 1):S35-S43.
24. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46:518-523.
25. Boger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl. 2003;4:1-3.
26. Martens-Lobenhoffer J, Bode-Boger SM. Measurement of asymmetric dimethylarginine (ADMA) in human plasma: from liquid chromatography estimation to liquid chromatography-mass spectrometry quantification. Eur J Clin Pharmacol. 2006;62(suppl 13):61-68.
27. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002;99:13527-13532.
28. Fu YF, Xiong Y, Guo Z. A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol. 2005;508:167-175.
29. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism. 2004;53:1574-1579.
30. Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, Hinz AV, D'Alecy LG. Contribution of Whole Blood to the Control of Plasma Asymmetrical Dimethylarginine. Am J Physiol Heart Circ Physiol. 2006;291:H1788-H1796.
31. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W, Schermuly RT. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005;19:1175-1177.
32. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol. 1995;269:C750-C756.
33. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023-1030.
34. Sydow K, Hornig B, Arakawa N, Bode-Boger SM, Tsikas D, Munzel T, Boger RH. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med. 2004;9:93-101.
35. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998;95:9220-9225.
36. Maffei A, Poulet R, Vecchione C, Colella S, Fratta L, Frati G, Trimarco V, Trimarco B, Lembo G. Increased basal nitric oxide release despite enhanced free radical production in hypertension. J Hypertens. 2002;20:1135-1142.
37. Rizzoni D. Endothelial dysfunction in hypertension: fact or fantasy? J Hypertens. 2002;20:1479-1481.
38. Haller H, Cosentino F, Luscher TF. Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine. Drugs R D. 2002;3:311-323.
39. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769-1775.
40. Yang Z, Kaye DM. Endothelial dysfunction and impaired L-arginine transport in hypertension and genetically predisposed normotensive subjects. Trends Cardiovasc Med. 2006;16:118-124.
41. Kopieczna-Grzebieniak E, Goss M. The importance of regulation of endogenous methylarginine concentrations in clinical practice [in Polish]. Przegl Lek. 2005;62:1494-1501.